Newscast – media

FDA Issues Safety Alert for Radiofrequency Microneedling

The U.S. Food and Drug Administration (FDA) is warning consumers, patients and healthcare providers about the potential risk for serious complications from radiofrequency (RF) microneedling procedures. RF microneedling devices are commonly used to improve skin appearance of the face and neck — often referred to as “resurfacing,” “tightening” or “rejuvenation” to treat issues like wrinkles. The technology works by using an array of tiny needles (microneedles) to deliver RF energy and heat into the skin. This heat is intended to cause controlled changes in the tissue, promoting new collagen growth, according to the FDA. However, the FDA has received numerous reports of serious and potentially permanent injuries related to the microneedling procedure. The adverse events reported to the agency include: Severe burns Permanent scarring Fat loss (diminishing facial volume) Physical disfigurement Nerve damage These reported injuries have occasionally required follow-up ...
- Source: HealthDay
- 65
- November 5, 2025
Antihypertensive and lipid-lowering drugs show efficacy against steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one third of the adult population. This disorder is characterized by the accumulation of fat in liver cells, which has severe liver consequences and is also associated with a high mortality rate from cardiovascular disease. Now, a University of Barcelona study published in the journal Pharmacological Research shows that pemafibrate and telmisartan, two drugs already approved for other conditions, effectively reduce fat accumulation in laboratory animal models of metabolic liver disease. Furthermore, the study suggests that this combination of drugs may help to reduce both liver involvement and associated cardiovascular complications. These results open the door to the development of safer and more effective treatments for this disease, for which current therapeutic options are very limited. The study has been carried out by a team led by Marta Alegret, professor at the ...
- Source: drugdu
- 157
- October 7, 2025
Large-scale analysis offers insights into sporadic nature of chikungunya virus outbreaks

While the virus is common in tropical and subtropical regions, including Asia, Africa and South America, public health officials have been tracking reported infections in Europe and, in September, a confirmed case in Long Island, New York. Outbreaks of chikungunya have prompted the Centers for Disease Control to issue health notices to travelers bound for Bangladesh; Cuba; Guangdong Province, China; Kenya; Madagascar; Somalia; and Sri Lanka. In Guangdong Province, an”unprecedented”outbreak recently prompted government officials in China to mandate quarantines for anyone suspected of being infected by the virus, spraying individuals with mosquito repellent and spraying impacted buildings and other areas with insecticide. In a new study, published in Science Advances, researchers at the University of Notre Dame analyzed more than 80 outbreaks of chikungunya virus to improve prediction of future outbreaks and inform vaccine trial development. “Chikungunya outbreaks are unpredictable in both size and severity,”said Alex ...
- Source: drugdu
- 136
- October 7, 2025
UK health agency urges people to get vaccinated against respiratory viruses before winter

The UK Health and Safety Agency (UKHSA) announced on the 26th that as winter approaches, influenzaThe number of cases of COVID-19, COVID-19 and respiratory syncytial virus (RSV) is on the rise, and the public is urged to make appointments for relevant vaccines as soon as possible. 　　The latest UK national influenza and COVID-19 surveillance report shows that related cases have been steadily increasing over the past few weeks. The COVID-19 positive rate has risen from 7.6% to 8.4% in one week, and the number of COVID-19 hospitalizations per 100,000 people has also increased from 2 to 2.73. UKHSA emphasizes that before the peak season of respiratory diseases arrives, people should receive timely medical treatment from the UK National Health Service.The free vaccinations are provided by the National Health Service (NHS). Pregnant women and millions of children are already eligible for the vaccine, and most eligible groups can make an appointment from October 1. This ...
- Source: https://finance.eastmoney.com/a/202509263525102518.html
- 138
- October 6, 2025
Beike Bio responded to the inquiry letter regarding its semi-annual report and detailed the reasons for the decline in herpes zoster vaccine sales.

Beike BioA response was made to the regulatory inquiry letter regarding information disclosure in the 2025 semi-annual report, mentioning the reasons for the decline in sales of shingles vaccine. 　　In the first half of 2025, the company’s operating income was 285 million yuan, a year-on-year decrease of 53.93%; the net profit was -73.5734 million yuan, turning from profit to loss year-on-year. The company disclosed that the decline in performance was mainly due to the decline in sales of shingles vaccine. 　　The announcement showed that during the reporting period, the company’s sales volume of shingles vaccine was -17,300 doses, with sales revenue of -65.2266 million yuan. 　　Beike Bio believes that factors such as product price structure, vaccination demand, low disease awareness, insufficient consumption willingness of the applicable group, and vaccine hesitation affect the product revenue. 　　The company stated in its response that during the reporting period, sales of herpes zoster vaccines decreased ...
- Source: https://finance.eastmoney.com/a/202509303526642756.html
- 142
- October 6, 2025
Dongcheng Pharmaceutical’s subsidiary’s new prostate cancer drug approved for clinical trials

Dongcheng Pharmaceutical recently announced that its controlling subsidiary, Lannacheng, has received approval from the National Medical Products Administration (NMPA) for the clinical trial of 225Ac-LNC1011 injection, authorizing it to conduct clinical trials for prostate cancer. This drug, an alpha-particle radioactive in vivo therapeutic targeting prostate-specific membrane antigen (PSMA), is intended for the treatment of patients with advanced prostate cancer who are PSMA-positive. Currently, no similar product is marketed outside of China , and no sales data is available. The project has invested approximately 14.53 million yuan in R&D. In completed animal and human trials, 225Ac-LNC1011 injection has demonstrated therapeutic potential for prostate cancer. However, the drug development cycle, clinical trial approval, and production are long and involve many steps. Investors need to be aware of the risk of drug development failure.
- Source: https://www.stcn.com/article/detail/3353547.html
- 141
- October 5, 2025
How Can AI Empower Medical B2B Trade? A Must-Try Industry Assistant

I. How Can AI Empower Medical B2B Trade? In global pharmaceutical and medical device B2B trade, challenges such as information opacity, complex compliance requirements, unpredictable market trends, and cross-border trade barriers have long troubled industry users. Businesses often invest significant time and effort in researching regulations, analyzing market data, and assessing procurement risks—precisely where AI can play a vital role. The launch of Drugdu AI marks a breakthrough in the application of AI in the pharmaceutical B2B sector. Developed by Drugdu.com, this intelligent industry assistant is powered by DeepSeek AI technology, designed to provide users with precise industry insights, regulatory guidance, and market trend analysis, ultimately optimizing procurement and supply chain decisions. But is Drugdu AI truly practical? What scenarios does it apply to? How accurate are its AI-generated responses? We conducted in-depth testing and summarized some practical usage recommendations for industry users. II. Drugdu AI Hands-on Experience: Core Feature Breakdown We ...
- Source: drugdu
- 550
- March 17, 2025
How AI Procurement Can Boost Supply Chain Efficiency by 50% in the Pharmaceutical Industry? Drugdu AI is Exploring the Future!

Traditional procurement faces high costs, lack of supply chain transparency, and complex compliance processes. Drugdu AI is developing intelligent procurement solutions to make pharmaceutical B2B purchasing more efficient and smarter! What is Drugdu AI? Drugdu AI is a leading B2B pharmaceutical procurement platform that has built a global database of pharmaceutical suppliers. By leveraging AI-driven decision-making and data-powered supply chain optimization, Drugdu AI aims to enhance matching accuracy and reduce procurement risks. Drugdu AI’s Core Capabilities 1. Global B2B Pharmaceutical Trading Platform Drugdu.com has built a digital procurement ecosystem covering pharmaceuticals, medical devices, and pharmaceutical raw materials. It seamlessly connects manufacturers, suppliers, and buyers worldwide, facilitating efficient cross-border transactions. 2. Intelligent Supply Chain Solutions The platform provides end-to-end services, including precise supplier matching, real-time price transparency, international logistics optimization, and inventory management—significantly shortening procurement cycles and reducing transaction costs. 3. Integrated Compliance & Certification Support Drugdu AI integrates FDA, GMP, ...
- Source: drugdu
- 623
- February 18, 2025
AI DeepSeek Drugdu AI intelligent procurement solutions pharma
How DeepSeek Helps You Succeed Efficiently

In recent years, the application of artificial intelligence has been transforming industries at an unprecedented pace. As a leading AI-powered Q&A assistant, DeepSeek has quickly become a trusted partner for professionals in global trade. Particularly in the complex field of pharmaceutical trade, DeepSeek provides a range of practical tools to help businesses accurately target markets, enhance efficiency, and mitigate risks. As a global leader in cross-border pharma trade, Drugdu.com has explored ways to integrate DeepSeek’s capabilities with industry needs, delivering more efficient solutions to its users. Here’s how DeepSeek can empower your pharma trade business: I. Accurate Market Insights: AI as Your Detective (1) Quickly Identify Customers and Markets: Wondering which Southeast Asian country has the highest demand for raw pharmaceutical ingredients? DeepSeek uses big data analysis to provide swift, accurate answers and even generates visual reports, saving you time compared to traditional customs data checks. (2) Monitor Competitors in Real-Time: With DeepSeek, ...
- Source: drugdu
- 484
- February 11, 2025
AI DeepSeek Drugdu Pharma Trade
How DeepSeek Helps You Succeed Efficiently

In recent years, the application of artificial intelligence has been transforming industries at an unprecedented pace. As a leading AI-powered Q&A assistant, DeepSeek has quickly become a trusted partner for professionals in global trade. Particularly in the complex field of pharmaceutical trade, DeepSeek provides a range of practical tools to help businesses accurately target markets, enhance efficiency, and mitigate risks. As a global leader in cross-border pharma trade, Drugdu.com has explored ways to integrate DeepSeek’s capabilities with industry needs, delivering more efficient solutions to its users. Here’s how DeepSeek can empower your pharma trade business: Accurate Market Insights: AI as Your Detective Quickly Identify Customers and Markets Wondering which Southeast Asian country has the highest demand for raw pharmaceutical ingredients? DeepSeek uses big data analysis to provide swift, accurate answers and even generates visual reports, saving you time compared to traditional customs data checks. Monitor Competitors in Real-Time With ...
- Source: drugdu
- 474
- February 10, 2025
AI DeepSeek Drugdu Pharma Trade

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.